Head to Head Contrast: Harrow (NASDAQ:HROW) vs. Lipocine (NASDAQ:LPCN)

Lipocine (NASDAQ:LPCN – Get Free Report) and Harrow (NASDAQ:HROW – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Risk & Volatility

Lipocine has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500. Comparatively, Harrow has a beta of 0.18, meaning that its stock price is 82% less volatile than the S&P 500.

Profitability

This table compares Lipocine and Harrow’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lipocine -249.23% -46.52% -41.75%
Harrow -9.39% -69.81% -5.16%

Insider and Institutional Ownership

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 72.8% of Harrow shares are owned by institutional investors. 4.7% of Lipocine shares are owned by insiders. Comparatively, 12.8% of Harrow shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Lipocine and Harrow, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipocine 1 1 1 0 2.00
Harrow 2 1 6 0 2.44

Lipocine currently has a consensus price target of $4.00, suggesting a potential upside of 170.27%. Harrow has a consensus price target of $66.20, suggesting a potential upside of 117.69%. Given Lipocine’s higher possible upside, equities research analysts plainly believe Lipocine is more favorable than Harrow.

Valuation and Earnings

This table compares Lipocine and Harrow”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lipocine $1.98 million 8.27 -$9.63 million ($1.28) -1.16
Harrow $272.30 million 4.19 -$5.14 million ($0.78) -38.99

Harrow has higher revenue and earnings than Lipocine. Harrow is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Summary

Harrow beats Lipocine on 9 of the 13 factors compared between the two stocks.

About Lipocine

(Get Free Report)

Lipocine Inc. is a biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral treatments for health conditions with significant unmet medical needs. Its proprietary drug-delivery technology is designed to enable medicines that may otherwise require different formulations or routes of administration to be taken orally. The company’s lead commercial-stage product is Tlando, an oral testosterone-replacement therapy approved in the United States for adult men with testosterone deficiency.

About Harrow

(Get Free Report)

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.